MCID: VLV011
MIFTS: 51

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15 17
Candidiasis of Vulva and Vagina 12 32
Candidiasis, Vulvovaginal 43 71
Candidiasis Vulvovaginal 54
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12
Candidal: Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD9CM 34 112.1
MeSH 43 D002181
NCIt 49 C2914
SNOMED-CT 67 72605008
ICD10 32 B37.3
UMLS 71 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a "vaginal yeast infection." Other names for this infection are "vaginal candidiasis," "vulvovaginal candidiasis," or "candidal vaginitis."

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis of vulva and vagina, is related to candida glabrata and vaginitis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Miconazole and Dequalinium have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and cervix, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 74 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 candida glabrata 31.5 SKAP2 IFNG
2 vaginitis 31.0 TLR2 LAP3 DEFB4A CCR6
3 vulvar vestibulitis syndrome 30.7 NLRP3 MBL2 IL1RN
4 cervicitis 30.5 TLR2 IL2 DEFB4A
5 bacterial vaginosis 30.5 TLR2 MBL2 LAP3 IL4 IL1RN DEFB4A
6 amyotrophic lateral sclerosis 3 30.4 SKAP2 CLEC7A CCR6
7 urethritis 30.3 TLR2 DEFB4A DEFA5
8 candidiasis 30.3 TLR2 SKAP2 MBL2 IL4 IL2 IFNG
9 immunoglobulin alpha deficiency 30.0 MBL2 CD79A CCR6
10 cutaneous candidiasis 29.7 CLEC7A CCR6 CARD9
11 acquired immunodeficiency syndrome 29.6 IL2 IFNG CD79A CCR6
12 dermatophytosis 29.4 DEFB4A CLEC7A CCR6 CARD9
13 immune deficiency disease 29.2 MBL2 IL4 IL2 IFNG CD79A CCR6
14 oral candidiasis 29.0 SKAP2 IL1RN DEFB4A DEFB1 CLEC7A CCR6
15 exanthem 28.8 NLRP3 IL2 IL1RN F2 CCR6
16 chronic mucocutaneous candidiasis 28.6 TLR2 IL4 IFNG CLEC7A CCR6 CARD9
17 vaginal disease 28.6 TLR2 SKAP2 IL2 DEFB4A CLEC7A CCR6
18 skin disease 28.6 TLR2 IL4 IL2 IFNG DEFB4A CD79A
19 bacterial infectious disease 28.1 TLR2 MBL2 LCN2 IL1RN IFNG DEFB4A
20 vulvovaginitis 10.9
21 vaginal discharge 10.8
22 immunoglobulin g deficiency 10.6 MBL2 CD79A
23 prosthetic joint infection 10.5 TLR2 MBL2
24 mycobacterium kansasii 10.5 TLR2 NLRP3
25 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.5 IL4 IL2
26 corneal abscess 10.4 DEFB4A DEFB1
27 trichomoniasis 10.4
28 overgrowth syndrome 10.4
29 fungal keratitis 10.4 TLR2 CLEC7A
30 haemophilus influenzae 10.4 TLR2 CLEC7A
31 virus associated hemophagocytic syndrome 10.4 IL4 IL2
32 mycobacterium abscessus 10.4 TLR2 NLRP3 CLEC7A
33 amebiasis 10.4 TLR2 IL4 CD79A
34 trichomonas vaginalis trichomoniasis 10.4
35 streptococcus pneumonia 10.4 TLR2 NLRP3 IL4
36 rheumatic heart disease 10.4 TLR2 MBL2 IL4
37 cryopyrin-associated periodic syndrome 10.3 NLRP3 IL1RN
38 jak3-deficient severe combined immunodeficiency 10.3 IL4 IL2
39 ige responsiveness, atopic 10.3
40 periapical granuloma 10.3 TLR2 IL4 IL2
41 tinea profunda 10.3 CLEC7A CARD9
42 neisseria meningitidis infection 10.3 TLR2 MBL2 IL1RN
43 agammaglobulinemia, x-linked 10.3 IL4 IL2 CD79A
44 fixed drug eruption 10.3 IL2 IFNG
45 chronic graft versus host disease 10.3 IFNG CD79A
46 b-cell growth factor 10.3 IL4 IFNG
47 membranous nephropathy 10.2 MBL2 LCN2 CD79A
48 cicatricial pemphigoid 10.2 IL4 IL1RN CD79A
49 inferolateral myocardial infarct 10.2 LCN2 GGT1
50 orofacial granulomatosis 10.2 IL4 IFNG CD79A

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 CARD9 CCR6 CD79A CLEC7A F2 GGT1
2 homeostasis/metabolism MP:0005376 10.1 CARD9 CCR6 CD79A CLEC7A F2 GGT1
3 immune system MP:0005387 10.06 CARD9 CCR6 CD79A CLEC7A F2 GGT1
4 liver/biliary system MP:0005370 9.5 CD79A IFNG IL2 IL4 LCN2 NLRP3
5 renal/urinary system MP:0005367 9.23 CD79A GGT1 IFNG IL4 LCN2 MBL2

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Dequalinium Approved, Investigational Phase 4 6707-58-0
3
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6 Antifungal Agents Phase 4
7 Steroid Synthesis Inhibitors Phase 4
8 Cytochrome P-450 Enzyme Inhibitors Phase 4
9 Hormone Antagonists Phase 4
10 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
11
Metronidazole Approved Phase 3 443-48-1 4173
12
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
13
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
14
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
15
Secnidazole Approved Phase 3 3366-95-8
16
Terconazole Approved Phase 3 67915-31-5 441383
17
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
18 Anti-Bacterial Agents Phase 3
19 Antiparasitic Agents Phase 3
20 Antiprotozoal Agents Phase 3
21 Liposomal amphotericin B Phase 3
22 Clindamycin phosphate Phase 3
23 Clindamycin palmitate Phase 3
24 Alkylating Agents Phase 3
25 Cytochrome P-450 CYP3A Inhibitors Phase 3
26
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
27
Titanium dioxide Approved Phase 2 13463-67-7
28
Metformin Approved Phase 2 657-24-9 4091 14219
29
Canagliflozin Approved Phase 2 842133-18-0
30 Vaccines Phase 1, Phase 2
31 Immunologic Factors Phase 1, Phase 2
32 Rezafungin Phase 2
33 Gastrointestinal Agents Phase 1, Phase 2
34 Anti-Ulcer Agents Phase 1, Phase 2
35 Adjuvants, Immunologic Phase 1, Phase 2
36 Antacids Phase 1, Phase 2
37 Hypoglycemic Agents Phase 2
38 HIV Protease Inhibitors Phase 2
39
protease inhibitors Phase 2
40 Sodium-Glucose Transporter 2 Inhibitors Phase 2
41 Sitagliptin Phosphate Phase 2
42 Incretins Phase 2
43 Dipeptidyl-Peptidase IV Inhibitors Phase 2
44 Anti-Obesity Agents Phase 2
45 Anti-Infective Agents Phase 2
46 Acidophilus Phase 1
47
Butoconazole Approved 64872-77-1, 64872-76-0 47472
48
Iron Approved, Experimental 7439-89-6, 15438-31-0 23925 27284
49
Itraconazole Approved, Investigational 84625-61-6 55283
50 Trace Elements

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
2 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
4 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
6 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
7 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
8 Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management Completed NCT00353561 Phase 3 Boric;Fluconazole
9 A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis. Completed NCT01806623 Phase 3 Fluconazole
10 An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
11 A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
12 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo. Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
13 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03734991 Phase 3 Ibrexafungerp;Placebo
14 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
15 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia. Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
16 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
17 Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
18 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
19 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03562156 Phase 3 VT-1161;Placebo
20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03561701 Phase 3 VT-1161;Placebo
21 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC). Recruiting NCT03987620 Phase 3 Ibrexafungerp;Placebo
22 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Recruiting NCT04029116 Phase 3 Fluconazole Tablet;IBREXAFUNGERP;Placebo oral tablet
23 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
24 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
25 Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
26 Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
27 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis Completed NCT02267382 Phase 2 VT-1161;Placebo
28 A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis Completed NCT01891331 Phase 2 VT-1161;Fluconazole
29 A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
30 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
31 A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
32 Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
33 A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
34 A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
35 A Randomized Single Blind Safety and Efficacy Study of TOL-463 Vaginal Gel or Insert in the Treatment of Vaginitis (BV and/or VVC) Completed NCT02866227 Phase 2 TOL-463;TOL-463
36 A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
37 A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm Completed NCT00642278 Phase 2 Canagliflozin (JNJ-28431754);Sitagliptin;Placebo
38 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects Completed NCT00650806 Phase 2 Canagliflozin (JNJ-28431754);Placebo
39 Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
40 A Randomized, Double-Blind, Placebo-Controlled Trial Of TOL-463 Insert for Suppression Of Bacterial Vaginosis (BV) [SUBVert] Recruiting NCT03930745 Phase 2 TOL-463
41 A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
42 A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
43 A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers Completed NCT01067131 Phase 1
44 Study Evaluating the Optimal Dosage for Equivalence Between a Tablet and Capsule Dosage Form of an Intravaginal Treatment With Total Freeze-dried Culture of Lcr Regenerans® (Lactobacillus Rhamnosus Lcr35®) on Vaginal Flora Colonisation in Healthy Women. Completed NCT02730494 Phase 1
45 A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
46 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046
47 "A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis" Unknown status NCT00417365
48 Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis Unknown status NCT02185456 Early Phase 1 750 mg metronidazole/ 200 mg miconazole vaginal suppository;Standard of care
49 A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis Completed NCT01039584 Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
50 A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02888197

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


butoconazole
Butoconazole nitrate
Clotrimazole
Fluconazole
Gentian Violet
Itraconazole
Ketoconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
NYSTATIN PWDR
terconazole
tioconazole

Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

40
Testes, Skin, Cervix, Colon, Neutrophil, T Cells, B Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 1126)
# Title Authors PMID Year
1
Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. 61 54
19910100 2010
2
Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. 54 61
18715406 2008
3
MBL2 genetic screening in patients with recurrent vaginal infections. 61 54
18211540 2008
4
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 54 61
17470593 2007
5
Mannose-binding lectin and vulvovaginal candidiasis. 54 61
16256117 2006
6
Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. 54 61
15825027 2005
7
Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. 61 54
12942410 2003
8
Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. 61
31299136 2020
9
Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. 61
31845594 2019
10
Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis. 61
31762516 2019
11
Vulvovaginal candidiasis among symptomatic women of childbearing age attended at a Medical Analysis Laboratory in Franceville, Gabon. 61
31481349 2019
12
The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. 61
31446677 2019
13
Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. 61
31663976 2019
14
The IL-17R/IL-22R signaling axis is dispensable for vulvovaginal candidiasis regardless of estrogen status. 61
31805183 2019
15
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation. 61
30945022 2019
16
Clinical Characteristics and Antifungal Susceptibility of Candida nivariensis from Vulvovaginal Candidiasis. 61
31694024 2019
17
Correction: Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. 61
31699752 2019
18
Cinnamaldehyde inhibits Candida albicans growth by causing apoptosis and its treatment on vulvovaginal candidiasis and oropharyngeal candidiasis. 61
31659418 2019
19
Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. 61
31451496 2019
20
A comparative analysis of protein virulence factors released via extracellular vesicles in two Candida albicans strains cultivated in a nutrient-limited medium. 61
31412284 2019
21
Clinical validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: results from a prospective multi-center clinical study. 61
31748322 2019
22
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. 61
31707496 2019
23
Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis. 61
31705810 2019
24
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. 61
29685081 2019
25
The Vaginal Microbiota and Behavioral Factors Associated With Genital Candida albicans Detection in Reproductive-Age Women. 61
31517769 2019
26
Prospective Evaluation of Molecular Assays for the Diagnosis of Vaginitis. 61
31694966 2019
27
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. 61
31812702 2019
28
Chitooligosaccharides and Thermostable Chitinase Against Vulvovaginal Candidiasis and Saprophyte Fungi: LC Mass Studies of Shrimp Shell Fermentation by Bacillus altitudinis. 61
31659402 2019
29
Association of sexual function and psychological symptoms (depression, anxiety and stress) in women with recurrent vulvovaginal candidiasis 61
31640303 2019
30
Bacterial vaginosis, vulvovaginal candidiasis and trichomonal vaginitis among reproductive-aged women seeking primary healthcare in Sana'a city, Yemen. 61
31640583 2019
31
Sunlight exposure, consumption of vitamin D-rich foods and vulvovaginal candidiasis in an African population: a prevalence case-control study. 61
31636409 2019
32
Should we absolutely reject the hypothesis that epithelium-based Candida biofilms contribute to the pathogenesis of human vulvovaginal candidiasis? 61
31283906 2019
33
Diversity of vaginal microbiome and metabolome during genital infections. 61
31575935 2019
34
Efficacy of curcumin in the treatment of experimental vulvovaginal candidiasis. 61
31757595 2019
35
Systematic analysis of protein expression in Candida albicans exposed to farnesol. 61
31503056 2019
36
Biodegradable cross-linked chitosan nanoparticles improve anti-Candida and anti-biofilm activity of TistH, a peptide identified in the venom gland of the Tityus stigmurus scorpion. 61
31349502 2019
37
Influence of recurrent vulvovaginal candidiasis on quality of life issues. 61
31270690 2019
38
Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis. 61
31158491 2019
39
Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: Are they different from normal microbiota? 61
31212037 2019
40
Noncandidal vaginitis: a comprehensive approach to diagnosis and management. 61
31513780 2019
41
Study on the prevalence and factors associated to vulvodynia in Spain. 61
31260857 2019
42
Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. 61
31547803 2019
43
Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women. 61
31502121 2019
44
Sweet Relief: Determining the Antimicrobial Activity of Medical Grade Honey Against Vaginal Isolates of Candida albicans. 61
31505796 2019
45
Antifungal and Antivirulence Activity of Vaginal Lactobacillus Spp. Products against Candida Vaginal Isolates. 61
31547398 2019
46
The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. 61
31330226 2019
47
Molecular Diagnosis of Vaginitis: Comparing Quantitative PCR and Microbiome Profiling Approaches to Current Microscopy Scoring. 61
31315951 2019
48
Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis. 61
31106557 2019
49
Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. 61
30656691 2019
50
Evaluation of reliability of self-collected vaginal swabs over physician-collected samples for diagnosis of bacterial vaginosis, candidiasis and trichomoniasis, in a resource-limited setting: a cross-sectional study in India. 61
31462459 2019

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 TLR2 NLRP3 MBL2 LCN2 IL4 IL2
2
Show member pathways
13.02 TLR2 NLRP3 MBL2 IL2 IFNG CARD9
3
Show member pathways
12.17 TLR2 LCN2 IL4 IFNG DEFB4A
4 12.14 NLRP3 DEFB4A DEFA5 CARD9
5 12.13 TLR2 IFNG CLEC7A CARD9
6
Show member pathways
12.13 IL4 IL2 IFNG GGT1 F2
7
Show member pathways
12.11 NLRP3 IL2 CLEC7A CARD9
8
Show member pathways
12.08 TLR2 IL4 IFNG DEFB4A
9
Show member pathways
12.07 TLR2 LCN2 DEFB4A DEFB1 DEFA5 CCR6
10
Show member pathways
11.94 TLR2 IL4 IFNG F2
11 11.88 IL4 IL2 IFNG CD79A
12 11.74 MBL2 DEFB4A DEFB1 DEFA5
13 11.69 IL4 IL2 IFNG
14 11.68 TLR2 IL4 IL2 IL1RN IFNG CD79A
15
Show member pathways
11.65 IL4 IL2 IFNG
16 11.57 IL4 IL2 IFNG CCR6
17 11.47 IL4 IL2 IL1RN IFNG
18 11.39 IL4 IL2 IFNG
19 11.22 IL4 IL2 IFNG
20 11.13 IL4 IL2 IFNG
21 11.07 IL4 IL2 IFNG
22 10.85 TLR2 NLRP3 IFNG F2

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 NLRP3 MBL2 LCN2 IL4 IL2 IL1RN
2 Golgi lumen GO:0005796 9.46 F2 DEFB4A DEFB1 DEFA5
3 extracellular space GO:0005615 9.36 MBL2 LCN2 IL4 IL2 IL1RN IFNG

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 TLR2 LCN2 IL4 IFNG CLEC7A
2 cellular response to lipopolysaccharide GO:0071222 9.87 NLRP3 LCN2 IL1RN DEFA5
3 immune system process GO:0002376 9.86 TLR2 NLRP3 MBL2 LCN2 IL2 CLEC7A
4 defense response GO:0006952 9.81 NLRP3 DEFB4A DEFB1 DEFA5
5 defense response to bacterium GO:0042742 9.8 MBL2 LCN2 DEFB4A DEFB1 DEFA5
6 defense response to Gram-negative bacterium GO:0050829 9.79 DEFB4A DEFB1 DEFA5
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 IL4 IL2 IFNG
8 innate immune response GO:0045087 9.76 TLR2 NLRP3 MBL2 LCN2 DEFB1 DEFA5
9 positive regulation of interleukin-6 production GO:0032755 9.75 TLR2 IL1RN CARD9
10 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.72 NLRP3 CLEC7A CARD9
11 positive regulation of phagocytosis GO:0050766 9.7 MBL2 IFNG CLEC7A
12 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.67 F2 DEFB4A DEFB1 DEFA5
13 antimicrobial humoral response GO:0019730 9.62 LCN2 DEFB4A DEFB1 DEFA5
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL4 IL2
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL4 IFNG
16 B cell activation GO:0042113 9.61 SKAP2 IL4 CD79A
17 positive regulation of interleukin-13 production GO:0032736 9.59 NLRP3 IL4
18 positive regulation of killing of cells of other organism GO:0051712 9.56 IFNG CLEC7A
19 immune response GO:0006955 9.56 TLR2 IL4 IL2 IL1RN IFNG DEFB4A
20 neuroinflammatory response GO:0150076 9.54 IL4 IFNG
21 positive regulation of cellular respiration GO:1901857 9.49 IL4 IFNG
22 cytokine secretion involved in immune response GO:0002374 9.48 TLR2 NLRP3
23 positive regulation of flagellated sperm motility involved in capacitation GO:0060474 9.46 DEFB1 CCR6
24 defense response to Gram-positive bacterium GO:0050830 9.17 TLR2 NLRP3 MBL2 DEFB4A DEFB1 DEFA5

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling pattern recognition receptor activity GO:0008329 9.16 TLR2 CLEC7A
2 CCR6 chemokine receptor binding GO:0031731 8.96 DEFB4A DEFB1
3 cytokine activity GO:0005125 8.92 IL4 IL2 IL1RN IFNG

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....